FDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilarGeneric drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is Share XFDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilarhttps://pharmaphorum.com/news/fda-okays-mylan-insulin-drug-as-first-interchangeable-biosimilar/
Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
Sanofi doubles down on mRNA jabs with €400m-a-year R&D driveSanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year Share XSanofi doubles down on mRNA jabs with €400m-a-year R&D drivehttps://pharmaphorum.com/news/sanofi-doubles-down-on-mrna-jabs-with-e400m-yearly-rd-drive/
AZ, Sanofi prep filings for one-shot RSV antibody after trial winAstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next Share XAZ, Sanofi prep filings for one-shot RSV antibody after trial winhttps://pharmaphorum.com/news/az-sanofi-prep-filings-for-one-shot-rsv-antibody-after-trial-win/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Sanofi and Translate take first mRNA flu vaccine into clinicSanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to Share XSanofi and Translate take first mRNA flu vaccine into clinichttps://pharmaphorum.com/news/sanofi-and-translate-take-first-mrna-flu-vaccine-into-clinic/
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MSSanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple Share XAfter FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MShttps://pharmaphorum.com/news/after-fda-rejection-eu-says-yes-to-sanofis-aubagio-in-children/
EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionSanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) Share XEHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionhttps://pharmaphorum.com/news/eha21-sanofi-builds-case-for-rare-disease-drug-sutimlimab-after-fda-rejection/
